The use of the NIS reporter gene for optimizing oncolytic virotherapy

Amber Miller, Stephen J Russell

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Introduction: Oncolytic viruses are experimental cancer therapies being translated to the clinic. They are unique in their ability to amplify within the body, therefore requiring careful monitoring of viral replication and biodistribution. Traditional monitoring strategies fail to recapitulate the dynamic nature of oncolytic virotherapy. Consequently, clinically relevant, noninvasive, high resolution strategies are needed to effectively track virotherapy in real time.Areas covered: The expression of the sodium iodide symporter (NIS) reporter gene is tightly coupled to viral genome replication and mediates radioisotope concentration, allowing noninvasive molecular nuclear imaging of active viral infection with high resolution. This provides insight into replication kinetics, biodistribution, the impact of vector design, administration, and dosing on therapeutic outcomes, and highlights the heterogeneity of spatial distribution and temporal evolution of infection. NIS-mediated imaging in clinical trials confirms the feasibility of this technology to noninvasively and longitudinally observe oncolytic virus infection, replication, and distribution.Expert opinion: NIS-mediated imaging provides detailed functional and molecular information on the evolution of oncolytic virus infection in living animals. The use of NIS reporter gene imaging has rapidly advanced to provide unparalleled insight into the spatial and temporal context of oncolytic infection which will be integral to optimization of oncolytic treatment strategies.

Original languageEnglish (US)
Pages (from-to)15-32
Number of pages18
JournalExpert Opinion on Biological Therapy
Volume16
Issue number1
DOIs
StatePublished - Jan 2 2016

Fingerprint

Oncolytic Virotherapy
Oncolytic Viruses
Virus Diseases
Reporter Genes
Genes
Viruses
Imaging techniques
Investigational Therapies
Molecular Imaging
Viral Genome
Expert Testimony
Virus Replication
Infection
Radioisotopes
Monitoring
Clinical Trials
Spatial distribution
Technology
Animals
Therapeutics

Keywords

  • molecular imaging
  • NIS
  • oncolytic virus
  • reporter gene

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

The use of the NIS reporter gene for optimizing oncolytic virotherapy. / Miller, Amber; Russell, Stephen J.

In: Expert Opinion on Biological Therapy, Vol. 16, No. 1, 02.01.2016, p. 15-32.

Research output: Contribution to journalArticle

@article{eb4396f3e06d417f985c312237ebd0ab,
title = "The use of the NIS reporter gene for optimizing oncolytic virotherapy",
abstract = "Introduction: Oncolytic viruses are experimental cancer therapies being translated to the clinic. They are unique in their ability to amplify within the body, therefore requiring careful monitoring of viral replication and biodistribution. Traditional monitoring strategies fail to recapitulate the dynamic nature of oncolytic virotherapy. Consequently, clinically relevant, noninvasive, high resolution strategies are needed to effectively track virotherapy in real time.Areas covered: The expression of the sodium iodide symporter (NIS) reporter gene is tightly coupled to viral genome replication and mediates radioisotope concentration, allowing noninvasive molecular nuclear imaging of active viral infection with high resolution. This provides insight into replication kinetics, biodistribution, the impact of vector design, administration, and dosing on therapeutic outcomes, and highlights the heterogeneity of spatial distribution and temporal evolution of infection. NIS-mediated imaging in clinical trials confirms the feasibility of this technology to noninvasively and longitudinally observe oncolytic virus infection, replication, and distribution.Expert opinion: NIS-mediated imaging provides detailed functional and molecular information on the evolution of oncolytic virus infection in living animals. The use of NIS reporter gene imaging has rapidly advanced to provide unparalleled insight into the spatial and temporal context of oncolytic infection which will be integral to optimization of oncolytic treatment strategies.",
keywords = "molecular imaging, NIS, oncolytic virus, reporter gene",
author = "Amber Miller and Russell, {Stephen J}",
year = "2016",
month = "1",
day = "2",
doi = "10.1517/14712598.2016.1100162",
language = "English (US)",
volume = "16",
pages = "15--32",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The use of the NIS reporter gene for optimizing oncolytic virotherapy

AU - Miller, Amber

AU - Russell, Stephen J

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Introduction: Oncolytic viruses are experimental cancer therapies being translated to the clinic. They are unique in their ability to amplify within the body, therefore requiring careful monitoring of viral replication and biodistribution. Traditional monitoring strategies fail to recapitulate the dynamic nature of oncolytic virotherapy. Consequently, clinically relevant, noninvasive, high resolution strategies are needed to effectively track virotherapy in real time.Areas covered: The expression of the sodium iodide symporter (NIS) reporter gene is tightly coupled to viral genome replication and mediates radioisotope concentration, allowing noninvasive molecular nuclear imaging of active viral infection with high resolution. This provides insight into replication kinetics, biodistribution, the impact of vector design, administration, and dosing on therapeutic outcomes, and highlights the heterogeneity of spatial distribution and temporal evolution of infection. NIS-mediated imaging in clinical trials confirms the feasibility of this technology to noninvasively and longitudinally observe oncolytic virus infection, replication, and distribution.Expert opinion: NIS-mediated imaging provides detailed functional and molecular information on the evolution of oncolytic virus infection in living animals. The use of NIS reporter gene imaging has rapidly advanced to provide unparalleled insight into the spatial and temporal context of oncolytic infection which will be integral to optimization of oncolytic treatment strategies.

AB - Introduction: Oncolytic viruses are experimental cancer therapies being translated to the clinic. They are unique in their ability to amplify within the body, therefore requiring careful monitoring of viral replication and biodistribution. Traditional monitoring strategies fail to recapitulate the dynamic nature of oncolytic virotherapy. Consequently, clinically relevant, noninvasive, high resolution strategies are needed to effectively track virotherapy in real time.Areas covered: The expression of the sodium iodide symporter (NIS) reporter gene is tightly coupled to viral genome replication and mediates radioisotope concentration, allowing noninvasive molecular nuclear imaging of active viral infection with high resolution. This provides insight into replication kinetics, biodistribution, the impact of vector design, administration, and dosing on therapeutic outcomes, and highlights the heterogeneity of spatial distribution and temporal evolution of infection. NIS-mediated imaging in clinical trials confirms the feasibility of this technology to noninvasively and longitudinally observe oncolytic virus infection, replication, and distribution.Expert opinion: NIS-mediated imaging provides detailed functional and molecular information on the evolution of oncolytic virus infection in living animals. The use of NIS reporter gene imaging has rapidly advanced to provide unparalleled insight into the spatial and temporal context of oncolytic infection which will be integral to optimization of oncolytic treatment strategies.

KW - molecular imaging

KW - NIS

KW - oncolytic virus

KW - reporter gene

UR - http://www.scopus.com/inward/record.url?scp=84955734092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955734092&partnerID=8YFLogxK

U2 - 10.1517/14712598.2016.1100162

DO - 10.1517/14712598.2016.1100162

M3 - Article

C2 - 26457362

AN - SCOPUS:84955734092

VL - 16

SP - 15

EP - 32

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -